De Wit R, Kulkarni GS, Uchio E, et al. Pembrolizumab for High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial. ESMO 2018, abstract 864O.
Intensiteit behandeling endeldarmkanker afgenomen
feb 2024 | Chirurgie, Endoscopie, Maag-darm-leveroncologie, Radiotherapie